Company Analysis
Sign in

Genmab A/S (GMAB)

Nasdaq: GMAB · Pharmaceutical Preparations · 1253 Copenhagen K, DK · filing with the SEC since 2008
Full chart Alerts Compare
Grade6.8
◀ Past 7.8● Present 6.9▶ Future 5.8
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$3.72B+19.2%
Net income$963M-15.0%
Earnings per share$15.37-12.3%
Operating cash flow$1.19B+5.3%
Cash$1.72B+24.3%
Debt$5.27B
Shareholders’ equity$5.85B+13.8%
Shares, diluted62.7M-3.0%
Return on equity16.5%
The recordfrom its filings
Filings in 202665
Newest filingNov 12 · 6-K
Annual reportFeb 17, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted157
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in USD. Nothing here is a forecast.

News

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton GMAB · research, not advice